)
Shares of healthcare companies have gained in today’s trade with drug maker Sun Pharma soaring over 3% on the BSE after the shareholders gave a nod to the merger of Sun Pharma Global with company.
Meanwhile, shares of Lupin have gained 1% on the BSE after receiving US FDA approval for producing generic Exforge HCT (used to treat high blood pressure) tablets. The company had launched the tablets in the month of April 2015.
Meanwhile, shares of Lupin have gained 1% on the BSE after receiving US FDA approval for producing generic Exforge HCT (used to treat high blood pressure) tablets. The company had launched the tablets in the month of April 2015.
Anuh Pharma has zoomed 16.4% on the BSE after the board of directors of the company decides to hold a meeting dated on 12 June, to consider issue of bonus shares.
Rare disease-focused unit of Sanofi, Genzyme picked up the FDA's coveted breakthrough-therapy designation for a drug designed to treat a form of Niemann-Pick disease. Sanofi India is up 2%.
Notable gainers on the BSE include Jubilant Lifesciences, Novartis India, Glenmark Pharma, Biocon, Natco Pharma, Aurobindo Pharma, Cipla, Dr Reddy’s Lab, Ipca Labs, Wockhardt, Strides Acrolab up between 0.5-4.5%.
Earlier during this week, Cipla received approval from United States Food & Drug Administration (USFDA) for an innovative formulation Lopinavir/ritonavir earlier during the week.
Aurobindo Pharma received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Metronidazole Tablets USP 250mg and 500mg (ANDA 203974).
